KPC PharmaceuticalsInc Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	2.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

KPC PharmaceuticalsInc non ha un CEO, o non abbiamo dati su di loro.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Ting Guo	Director	1.8yrs	Nessun dato	Nessun dato
Hui Zhou	Director	1.1yrs	Nessun dato	Nessun dato
Huawei Qiu	Chairman	1.8yrs	Nessun dato	Nessun dato
Jin Guo Xin	Independent Director	2.9yrs	CN¥100.00k	Nessun dato
Ke Liu	Independent Director	6yrs	CN¥100.00k	Nessun dato
Zheng Liang	Director	1.8yrs	Nessun dato	Nessun dato
Li Lin Xi	Employee Supervisor	6yrs	Nessun dato	Nessun dato
Zhang Weng Sen	Employee Supervisor	6yrs	Nessun dato	Nessun dato
Hongshen Li	Vice Chairman	less than a year	Nessun dato	Nessun dato
Zhi Yang	Independent Director	2.9yrs	CN¥100.00k	Nessun dato
Kang Deng	Supervisor	3.6yrs	Nessun dato	Nessun dato

2.9yrs

Durata media

52yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 600422 non è considerato esperto (durata media del mandato 2.9 anni), il che suggerisce un nuovo consiglio.

KPC PharmaceuticalsInc Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

KPC Pharmaceuticals,Inc, Annual General Meeting, Jun 21, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.22 in 3Q 2023)

KPC Pharmaceuticals,Inc. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 20%

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 2Q 2023)

Investor sentiment deteriorates as stock falls 16%

Dividend increased to CN¥0.20

KPC Pharmaceuticals,Inc. to Report First Half, 2024 Results on Aug 23, 2024

KPC Pharmaceuticals,Inc, Annual General Meeting, Jun 21, 2024

KPC Pharmaceuticals,Inc to Report Q1, 2024 Results on Apr 27, 2024

Full year 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.51 in FY 2022)

KPC Pharmaceuticals,Inc to Report Fiscal Year 2023 Results on Mar 22, 2024

Third quarter 2023 earnings released

Investor sentiment improves as stock rises 16%

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.14 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 16%

KPC Pharmaceuticals,Inc to Report First Half, 2023 Results on Aug 30, 2023

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 15%

Full year 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.67 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.13 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.18 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

First quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.26 in 1Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.17 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.17 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.12 in 1Q 2020)

New Hope Healthcare Nanjing Investment Center (Limited Partnership) signed an agreement to acquire 3.7% stake in Nanjing Weili Zhibo Biotechnology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for CNY 30 million.

Full year 2020 earnings released: EPS CN¥0.60 (vs CN¥0.60 in FY 2019)

New 90-day low: CN¥8.34

KPC Pharmaceuticals, Inc. to Report Fiscal Year 2020 Results on Mar 16, 2021

New 90-day low: CN¥8.38

New 90-day low: CN¥9.12

New 90-day low: CN¥9.54

Third quarter earnings released

KPC Pharmaceuticals, Inc. to Report Q3, 2020 Results on Oct 22, 2020

A group of buyers agreed to acquire 51% stake in Kunming Yinnuo Pharmaceutical Technology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for approximately CNY 170 million.

KPC Pharmaceuticals, Inc. (SHSE:600422) cancelled the acquisition of 30% stake in Zhejiang Holley Nanhu Pharmaceutical Co., Ltd.

First half earnings released

KPC Pharmaceuticals, Inc. to Report First Half, 2020 Results on Aug 21, 2020

AMMINISTRATORE DELEGATO

Membri del Consiglio di amministrazione

Durata media

Età media